Drug intelligence / Profile preview

dexmedetomidine + rocuronium

Development stage
Phase 3
Modality
Small Molecules
Administration
Intravenous
01

Overview

This is a combination of two medications used in anesthesia practice:\n\n**Dexmedetomidine** is a highly selective α2-adrenergic receptor agonist that provides sedation, anxiolysis, and analgesia without causing respiratory depression. It works by decreasing activity of noradrenergic neurons in the locus ceruleus, increasing inhibitory GABA neuron activity.\n\n**Rocuronium** is an aminosteroid non-depolarizing neuromuscular blocking agent used to facilitate endotracheal intubation and provide skeletal muscle relaxation during surgery or mechanical ventilation.\n\nStudies have shown that dexmedetomidine can influence the effects of rocuronium by potentially enhancing neuromuscular blockade. Research indicates that dexmedetomidine may increase plasma rocuronium concentration and decrease the first response (T1) in train-of-four monitoring, suggesting it may alter rocuronium's pharmacokinetics through vasoconstriction. Additionally, dexmedetomidine has been found to reduce pain associated with rocuronium injection and may shorten the onset time of rocuronium-induced neuromuscular blockade.

Brand names
Precedex + Zemuron
Other names
dexmedetomidine and rocuronium
02

Targets

Muscle-type nicotinic acetylcholine receptorADRA2A (α2A)

Beyond the preview

Go deeper on dexmedetomidine + rocuronium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dexmedetomidine + rocuronium.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call